A5031879677- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Angiogenesis and VEGF in Cancer
- Blood properties and coagulation
- Neutropenia and Cancer Infections
- Cancer therapeutics and mechanisms
- Peripheral Artery Disease Management
- Erythrocyte Function and Pathophysiology
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Drug Transport and Resistance Mechanisms
- Antifungal resistance and susceptibility
- Hematological disorders and diagnostics
- Lymphoma Diagnosis and Treatment
- Mesenchymal stem cell research
- Complement system in diseases
- Immunodeficiency and Autoimmune Disorders
- Digital Imaging for Blood Diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Medical and Biological Ozone Research
Shanghai Cell Therapy Research Institute
2017
Hôpital Robert-Debré
1984-2016
Hémostase et Dynamique Cellulaire Vasculaire
2016
Université de Reims Champagne-Ardenne
1992-2015
Centre Hospitalier Universitaire de Reims
1992-2015
Hôpital Maison Blanche
2007
Centre Hospitalier Universitaire de Tours
1996-2003
Centre Hospitalier Universitaire de Grenoble
2003
Laboratoire de Thermique et Energie de Nantes
2001
Groupe Francophone des Myélodysplasies
1999
PURPOSE To compare progression-free survival (PFS), overall (OS), and toxicity of a doxorubicin-containing regimen administered alone or in combination with interferon alfa-2b (IFNalpha) patients low-grade follicular lymphoma (FL) poor prognostic factors. PATIENTS AND METHODS Two hundred sixty-eight advanced-stage FL received cyclophosphamide, doxorubicin, teniposide, prednisone (CHVP) monthly for 6 months, then every 2 months 12 months. After randomization, 242 were evaluated efficacy: 119...
Background:Cell therapy is a therapeutic option for patients presenting with nonrevascularizable critical limb ischemia (CLI). However there lack of firm evidence on its efficacy because the paucity randomized controlled trials.
Autologous transplantation of either bone marrow (BM) or peripheral blood (PB) mononuclear cells (MNC) induces therapeutic angiogenesis in patients with arterial occlusive disease. Yet, the precise nature cellular product obtained from BM PB and used these strategies remains unclear.We have analysed characteristics BM-MNC PB-MNC collected without mobilization implanted critical limb ischaemia a clinical trial therapy including 16 individuals treated by eight PB-MNC. These MNCs were...
Eighteen French centers reported 133 autologous stem cell transplantations performed after first remission induction in multiple myeloma. The source of was marrow (81 cases), blood (51 cases) or plus (1 case). immediate outcome transplantation 49 (37%) complete remissions (CR; 13 maintained, 36 achieved), 61 (46%) partial remissions, 17 failures and 5 toxic deaths. With a median follow up 35 months, the duration 33 time to treatment failure 22 months. overall survival 46 54 months for 103...
BACKGROUND Despite modern treatment programs, less than 20% of adult cases acute lymphoblastic leukemia (ALL) are cured. For relapsing and/or refractory patients, use high dose cytosine arabinoside (ara-C) and anthracyclin achieved a complete remission (CR) rate up to 75%. The aim this study was evaluate in patients with ALL 1) the CR chemotherapy schedule similar for myeloblastic (AML) 2) antileukemic value tolerance 3 intensive stage treatments, 3) impact recombinant...
Despite modern treatment programs, less than 20% of adult cases acute lymphoblastic leukemia (ALL) are cured. For relapsing and/or refractory patients, use high dose cytosine arabinoside (ara-C) and anthracyclin achieved a complete remission (CR) rate up to 75%. The aim this study was evaluate in patients with ALL 1) the CR chemotherapy schedule similar for myeloblastic (AML) 2) antileukemic value tolerance 3 intensive stage treatments, 3) impact recombinant granulocyte-macrophage-colony...
Cell therapy is an emerging potential biotherapy for critical limb ischaemia (CLI) patients who are not eligible revascularization. However, the findings on this technique's efficacy inconsistent. Trials investigating topic focused more severe CLI were often beyond any therapy. Therefore, identifying those may truly benefit from cell transplantation now warranted. To end, we studied prognostic value of tcPO2 major amputation after 1 year in treated with bone marrow-derived cells.CLI...
BACKGROUND Cell therapy has been proposed as a salvage limb procedure in critical ischemia (CLI). Autologous cell products (CTP) are obtained from patients with advanced peripheral arterial disease to be injected at the site of ischemia. Thrombogenicity CTPs not yet assessed. The objectives were: 1) assess thrombotic risk candidates for therapy, 2) evaluate two different terms thrombogenic potential, and 3) clinical events. STUDY DESIGN AND METHODS In this ancillary study Phase I II trial,...